Ira M. Jacobson, M.D.

Hepatology
Ira Jacobson

Ira Jacobson, M.D. is Chief of the Division of Gastroenterology and Hepatology, Vincent Astor Distinguished Professor of Medicine, The Joan Sanford I. Weill Medical College of Cornell University, & Attending Physician, NewYork-PresbyterianHospitalCornell Campus. Dr. Jacobson is board certified in internal medicine and gastroenterology, and is a world-renowned expert in Hepatology and Liver Disease. He is the Medical Director for the Center for the Study of Hepatitis C, and is a principal investigator on many important trials involving antiviral therapy for both hepatitis B and C. He has published two textbooks: ERCP and Its Applications, Lippencott and Raven, 1998, and ERCP Diagnostic and Therapeutic Applications, Elsevier,1989. His special interests include hepatology, and endoscopy.

Dr. Jacobson, Chief of the Division of Gastroenterology and Hepatology, Vincent Astor Distinguished Professor of Medicine, Sanford I. Weill Medical College of Cornell University, and Attending Physician, NewYork-Presbyterian Hospital, Cornell Campus, is a world-renowned expert in Hepatology and Liver Disease. Dr. Jacboson graduated summa cum laude from Yale University and received his medical degree from Columbia University College of Physicians and Surgeons. Dr. Jacobson completed his residency in Internal Medicine at the University of California in San Francisco, where he received his Internal Medicine Board Certification. He then completed a Fellowship in Gastroenterology at Massachusetts General Hospital and Harvard Medical School and received his Gastroenterology Board Certification the following year.

In addition to serving as Chief of Gastroenterology and Hepatology, Dr. Jacobson has an active practice and serves as a principal investigator on many important trials involving antiviral therapy for both hepatitis B and C. Dr. Jacobson has published two of the leading textbooks in his field: ERCP and Its Applications, Lippencott and Raven, 1998, and ERCP Diagnostic and Therapeutic Applications, Elsevier, 1989. He has given numerous lectures and presentations, seminars and study groups at Cornell and throughout New York metropolitan area. He is currently a member of the American Board of Internal Medicine (ABIM).

Insurances

Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please feel free to contact this physician or this physician's practice as they may have individual contracts not included on this site.

  • Aetna - Weill Cornell [POS]
  • Medicare [Medicare]
  • Rockefeller University - CoreSource

Publications

BOOKS

1.   Jacobson IM, ed: ERCP: Diagnostic and Therapeutic Applications. New York: Elsevier, 1989.

2.   Jacobson IM, ed: ERCP and its Applications, Philadelphia: Lippincott-Raven, 1998.

PAPERS   

1.   Jacobson IM, Dienstag JL: Non-A, non-B hepatitis: clinical features and sequelae. Res. Staff Phys.1984; 30:33-44.

2.   Jacobson IM, Dienstag JL: The delta hepatitis virus: Viral hepatitis, type D. Gastroenterology 1984; 86:1614-17.

3.   Jacobson IM, Gang DL, Schapiro RH: Epstein-Barr viral hepatitis: An unusual case and review of the literature. Am J Gastroenterology 1984;79:628-32.

4.   Jacobson IM, Dienstag JL, Zachoval R, Hanrahan BA, Watkins E, Rubin RH: Lack of effect of hepatitis B vaccine on T-cell Phenotypes. N Engl J Med 1984;311:1030-32.

5.   Jacobson IM, Kelsey PB, Blyden G, Demirjian Z, Isselbacher KJ: Sulfasalazine-induced agranulocytosis. Am J Gastroenterology 1985;80:118-21.

6.   Jacobson IM, Dienstag, JL: Viral hepatitis vaccines. Am Rev Med 1985;36:241-61.

7.   Jacobson IM, Dienstag, JL, Werner, BG, Brettler D, Levine P, Mushahwar IK: Epidemiology of hepatitis D (delta) infection. Hepatology 1985;5:118-21.

8.   Ross ME, Jacobson IM, Dienstag JL, Martin JB: Late onset Wilson's disease with neurologic involvement in the absence of Kayser-Fleischer rings. Ann Neurol 1985;17:411-13.

9.   Jacobson IM, Nath BJ, Dienstag JL: Relapsing viral hepatitis type A. J Med Virol 1985;16:163-69.

10.   Jacobson IM, Jaffers G, Dienstag JL et al: Immunogenicity of hepatitis B vaccine in renal transplant recipients. Transplantation 1985;39:393-95.

11.   Jacobson IM, Schapiro RH, Warshaw AL: Gastric and duodenal fistulae in Crohn's disease. Gastroenterology 1985;89:1347-52.

12.   Margulis SJ, Honig CL, Soave R, Govoni AF, Mouradian JA, Jacobson IM: Biliary tract obstruction in the acquired immunodeficiency syndrome. Ann Int Med 1986;105:207-10.

13.   Margulis SJ, Jacobson IM: Preventing infectious complications of endoscopic retrograde cholangiopancreatography. Infections in Surgery 1988;127-130.

14.   Weg AL, Jacobson IM: Type D hepatitis. Medical Aspects of Human Sexuality 1988;22:49-51.

15.   Jacobson IM, Friedman LS: Viral hepatitis. Current Opinion in Infectious Diseases 1989;2:272-86.

16.   Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Jr., Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, Van Thiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A, and the Hepatitis Interventional Therapy Group: Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized controlled trial. N Engl J Med 1989;321:1501-6.

17.   Staiano-Coico L, Wong R, Ngoi SS, Jacobson IM, Morrissey KP, Leser ML, Gareen IF, McMahon C, Cennerazzo W, DeCosse JJ: DNA content of rectal scrapings from individuals at low and high risk for the development of colorectal cancer: a feasibility study. Cancer 1989; 64:2579-84.

18.   Scudera PL, Koizumi J, Jacobson IM: Brush cytology evaluation of lesions encountered during ERCP. Gastrointestinal Endoscopy 1990;36:281-84.

19.   Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC, Jr., Lindsay K, Payne J, Dienstag JL, O'Brien C, Tamburro C, Jacobson IM, Sampliner R, Feit D, Lefkowitch J, Kuhns M, Meschievitz C, Sanghvi B, Albrecht J, Gibas A, and the Hepatitis Interventional Therapy Group: A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323:295-301.

20.   Margulis SJ, Jacobson IM: Hepatobiliary and pancreatic manifestations of AIDS. Seminars in Gastrointestinal Disease 1991;2:49-61.

21.   Lefkowitch JH, Schiff ER, Davis GL, Perrillo RP, Lindsay K, Bodenheimer HC, Jr., Balart, LA, Ortego TJ, Payne J, Dienstag JL, Gibas A, Jacobson IM, Tamburro CH, Carey W, O'Brien C, Sampliner R, Van Thiel DH, Feit D, Albrecht J, Meschievitz C, Sanghvi B, Vaughan RD, and the Hepatitis Interventional Study Group: Pathological diagnosis of chronic hepatitis C: A multicenter comparative study with chronic hepatitis B. Gastroenterology 1991;104:595-603.

22.   Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, Van Thiel DH, Tamburro C, Martino FP, Sanghvi B, Albrecht JL: Assessing health-related quality of life in chronic hepatitis C using the sickness impact profile. Clinical Therapeutics 1994;16:334-43.

23.   Davis Gl, Lindsay K, Albrecht J, Bodenheimer HC, Balart LA, Perrillo RP, Dienstag JL, Tamburro C, Schiff ER, Carey W, Payne J, Jacobson IM, Van Thiel DH, Lefkowitch J, Sanghvi B and the Hepatitis Interventional Therapy Group: Clinical predictors of response to recombinant alpha interferon treatment in patients with chronic non-A, non-B hepatitis (hepatitis C). J. Viral Hepatitis 1994;1(1):55-63.

24.   Choi YH, Menken FA, Jacobson IM, Lombardo F, Kazam E, Barie PS: Recurrent acute pancreatitis: an additional manifestation of the "wandering spleen" syndrome. Am J Gastroenterology 1996; 91:1034-8.

25.   Tighe M, Jacobson IM: Bleeding from bile duct varices: an unexpected hazard during therapeutic ERCP. Gastrointestinal Endoscopy 1996;43:250-252.

26.   Roston A, Jacobson IM: Evaluation of the pattern of liver tests and yield of cholangiography in symptomatic choledocholithiasis: a prospective study. Gastrointestinal Endoscopy 1997; 45: 394-99.

27.   McHutchison JG, Gordon SC, Schiff ER et al: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New Engl J Med 1998;339:1485-92 (PI in Study Group).

      

28.   Davis GL, Esteban-Mur R, Rustgi V et al: Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. New Engl J Med 1998;339:1493- 99 (PI in Study Group).

               

29.   Dienstag JL, et al: Lamivudine as initial treatment for chronic hepatitis B in the Unites States. New Engl J Med 1999:341(17):1256-1264.

30.   Jacobson IM: Management of interferon relapsers. The American Journal of Medicine 1999; 107 (6B):62S-66S.

   

31.   Landzberg BR, Jacobson IM: An unusual case of acute colitis. The Lancet 2000; Vol 355: 1786.

32.   Min AD, Jones, JL, Esposito S, Lebovics E, Jacobson IM, Klion FM, Goldman IS, Geders JM, Tobias H, Bodian C, Bodenheimer HC: Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone. Am J of Gastroenterology 2001; Vol 96 (4):1143–1149.

33.   Manns MP, McHutchison JG, Gordon SC, et al : Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet, 2001;358:958-65 (PI in Study Group).

34.   Lindsay KL, Trepo C, Heintges T et al: A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa 2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34:395-403 (PI in Study Group).

   35.   Catalano MF, Geenen JE, Lehman GA, Siegel JH, Jacobs L, McKinley MJ, Raijman I, Meier P, Jacobson I, Kozarek R, Al-Kawas FH, Lo SK, Dua KS,Gaille J, Ginsberg GG, Parsons W, Meyerson SM, Cohen S, Nelson DB, McHattie JD, Carr-Kocke C: “Tannenbaum” Teflon stents versus traditional polyethylene stents for treatment of malignant biliary stricture. Gastrointestinal Endoscopy 2002; 55:345-358.

   

   36.    Kumar KS, Russo MW, Borczuk AC, Brown M, Esposito SP, Lobritto SJ, Jacobson IM, Brown RS: Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterology 2002; 97:2432-40.

   

37.   Rivadeneira DE, Pochapin MB, Grobmyer SR, Lieberman MD; Christos PJ, Jacobson I, Daly JM: Comparison of linear array endoscopic ultrasound and helical computed tomography for the staging of periampullary malignancies. Annals of Surgical Oncology. 2003;10(8):890-897.    

38.   Marcellin P., Chang T., Lim SG., Tong MJ., Sievert W., Shiffman ML., Jeffers L., Goodman Z., Wulfsohn MS., Xiong S., Fry J., Brosgart CL., for the Adefovir Dipivoxil 437 Study Group: Adefovir Dipivoxil for the treatment of hepatitis B e antigen–positive chronic hepatitis B; N Engl J Med 2003; (9) 348:808-816.

39.   Schiff ER, et al: Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. Journal of Hepatology 2003; 38 (6) 818-826 (PI in Study Group)

40.   Ni J, Hembrador E, Bisceglie AM, Jacobson IM, Talal A, Butera D, Rice CM, Chambers TJ, Dustin LB: Accumulation of B lymphocytes with a naïve, resting phenotype in a subset of hepatitis C patients. Journal of Immunology 2003; 170:3429-3439.

41.   Russo MW, Sood A, Jacobson IM, Brown RS Jr: Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality. Am J Gastroenterol. 2003;98(11):2521-7.

42.   Russo MW, Goldsweig C. Jacobson IM, Brown RS. Jr: A meta-analysis of interferon therapy for patients with chronic hepatitis C on hemodialysis. Am J Gasroenterol 2003; 98 (7):1610-1615.

43.   Russo MW, Jacobson IM: How to use statins in patients with chronic liver disease.

   Cleveland Clinic Journal of Medicine 2004; 71(1):58-62.

44.   Longman RS, Talal AH, Jacobson IM, Albert ML, and Rice C:. Presence of functional dendritic cells in patients chronically infected with hepatitis C virus. Blood 2004; 103: 1026 - 1029.

45.   Keeffe EB, Dieterich DT, Han SB, Jacobson IM, Martin P, Schiff ER, Tobias H, Wright T: A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clinical Gastroenterology and Hepatology 2004; 2:87-106.

46.   Canchis PW, Gonzalez SA, Fiel MI, Chiriboga L, Yee H. Edlin BR, Jacobson IM, Talal AH: Hepatocyte proliferation in chronic hepatitis C: correlation with degree of liver disease and serum -fetoprotein. Liver International 2004; 24:198-203.

47.   Canchis PW, Yee HT, Fiel MI, Dieterich DT, Liu RC, Chiriboga L, Jacobson IM, Edlin BR, Talal AH: Intrahepatic CD4 cell depletion in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr, 2004; 37(1):1125-1131.

   

48.   Lin AW, Gonzalez SA, Cunningham-Rundles S, Dorante G, Marshall S, Tignor A, H C, Jacobson IM, Talal AH: CD56 dim and CD56 bright cell activation and apoptosis in hepatitis C virus infection, Clin Exp Immunol 2004;137(2):408-416.

49.    Jacobson IM, Ahmed F, Russo MW, Lebovics E, Dieterich DT, Esposito SP, Bach N, Klion F, Tobias H, Antignano L, Brown RS Jr, Gabbaizadeh D, Geders J, Levendoglu H: Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT. Am J Gastroenterol. 2004; 99(9):1700-5.

50.   Patel K, Gordon SC, Jacobson I, Hezode C, Oh E, Smith KM, Pawlotsky JM, McHutchison JG: Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients, Journal of Hepatology 2004; 41(6): 935-942.

   

   51.   Ahmed F, Petrovic L, Rosen E, Gonzalez R, Jacobson IM: Fenofribrate-induced cirrhosis Letter to the Editor, Digestive Diseases and Sciences 2005, 50(2):312-313.

   

52.   Raison C.L., Broadwell S.D., Borisov A.S., Manatunga A.K., Capuron L.C., Woolwine B.J., Jacobson IM., Nemeroff C.B., Miller A.H: Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun. 2005;19(1):23-7.

53.   Raison CL, Borisov AS, Broadwell SD, Capuron LC, Woolwine BJ, Jacobson IM, Nemeroff C.B., Miller AH: Depression during pegylated IFN-alpha plus ribavirin therapy: prevalence and prediction. Journal of Clinical Psychiatry, 2005; 66(1):41-8.

   

54.   Longman RS, Talal AH, Jacobson IM, Rice CM, Albert ML: Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C. J Infect Dis. 2005; 1;192(3):497-503.

55.   Butera D, Marukian S, Iwamaye AE, Hembrador E, Chambers TJ, Di Bisceglie AM, Charles ED, Talal AH, Jacobson IM, Rice CM, Dustin LB: Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood 2005; 15;106(4):1175-82.

56.   Gonzalez SA, Jacobson IM: Clinical course of chronic hepatitis C in patients with very high serum alpha-fetoprotein levels and normal hepatic imaging. Am J Gastroenterol. 2005;100(4):977-8.

57.    Jacobson IM, Gonzalez SA, Ahmed F, Lebovics E, Min A,et al: A randomized trial of pegylated interferon alfa-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 2005; 100:2453-2462.

58.   Jacobson IM: Therapeutic options for chronic hepatitis B: Considerations and controversies. Am J Gastroenterology 2006:101 (S1):S13-S18.

59.   Gonzalez AG, Liu R, Edlin BR, Jacobson IM, Talal AH: HIV/Hepatitis C virus-coinfected patients with normal alanine aminotransferase levels. J Acquir Immune Defic Syndr. 2006; 41(5):582-589.

60.   Keeffe EB, Dieterich DT, Han SB, Jacobson IM, Martin P, Schiff ER, Tobias H, Wright TL: A treatment algorithm for the management of chronic hepatitis B virus infection in the United Sates: An update. Clinical Gastroenterology and Hepatology 2006; 4:936-962.

61.   Sigal S, Jacobson I: Future therapies for hepatitis C: where do we go from here? Nature Clinical Practice Gastroenterology and Hepatology, 2007; 4(2) 60-61.

62.   Kadam JS, Gonzalez SA, Ahmed F, Menezes A, Jacobson IM: Prognostic significance of hepatitis C virus RNA detection by transcription-mediated amplification with negative polymerase chain reaction during therapy with peginterferon α and ribavirin. Digestive Diseases and Sciences 2007, in press.

63.   Jacobson IM, Brown RS Jr, McCone J, Black M, Albert C, Dragutsky MS, Siddiqui FA,    Hargrave T, Kwo PY, Lambiase L, Galler GW, Araya V, Freilich B, Harvey J, Griffel L,    Brass C, WIN-R Study Group: Impact of weight based ribavirin with pegylated alfa-2b in    African Americans with HCV genotype 1. Hepatology 2007, in press.

64.   Jacobson IM, Brown RS Jr, Freilich B, Afdhal N, Kwo P, Santoro J, Becker S, Wakil A,    Pound D, Godofsky E, Strauss R, Bernstein D, Flamm S, Pauly MP, Mukhopadhyay P,    Griffel LH, Brass CA, WIN-R Study Group: Peginterferon alfa-2b and weight-based    versus flat dosing of ribavirin in patients with chronic hepatitis C. Hepatology 2007, in    press.

65.   Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, Gane EJ, Jacobson IM,    Lim SG, Naoumov N, Marcellin P , Piratvisuth T, Zoulim F: Management of patients    receiving oral therapy for chronic hepatitis B: report of a workshop. Clinical    Gastroenterology and Hepatology, 2007, in press.

   CHAPTERS AND REVIEWS

   

   1.   Jacobson IM: Nonsurgical treatment of biliary tract diseases, In: Zakim D, Boyer T, eds: Hepatology, 2nd ed., Philadelphia: Saunders, 1989;1548-60.

2.   Jacobson IM, Barie PS: Diseases of the biliary tract. In: Zakim D, Boyer T, eds: Hepatology, 2nd ed., Philadelphia: Saunders, 1989;1532-47.

   3.   Barie PS, Jacobson IM: Diseases of the Gallbladder. In: Zakim D, Boyer T, eds: Hepatology, 2nds ed., Philadelphia: Saunders, 1989;1532-46.

   

   4.   Jacobson IM: Endoscopic sphincterotomy in patients with intact gallbladders. In: Jacobson IM, ed.: ERCP: Diagnostic and Therapeutic Applications. New York: Elsevier, 1989; 127-138.

   

   5.   Ingber S, Jacobson IM: Biliary and pancreatic disease in the elderly. In: Friedman LS, ed.: Gastrointestinal diseases in the elderly. Gastro Clin N Am 1990; 19:433-58.

   

6.   Nestler JL, Jacobson IM: Disorders of the gallbladder and bile ducts. In: Conn R, ed.:

   Current Diagnosis 8; Philadelphia, Saunders, 1991; 745-51.

   7.   Jacobson IM: Liver. In: The New Book of Knowledge: Health and Medicine Annual: Grolier; 1992; 285-86.

   

   8.   Jacobson IM: Fulminant hepatic failure. In: Barie PS, Shires GT, eds.: Surgical Intensive Care. Boston. Little, Brown and Co., 1993; 801-818.

   

    9.   Jacobson IM: Liver. In: The New Book of Knowledge: Health and Medicine Annual: Grolier; 1993.

   

   10.   Jacobson IM: "ERCP and the pancreas," Clinical Advances in Gastroenterology, audiotape update program of American College of Gastroenterology, 1993.

   

   11.   Jacobson IM: Liver. In: The New Book of Knowledge: Health and Medicine Annual: Grolier, 1994.

   

   12.   Jacobson IM: Liver. In: The New Book of Knowledge: Health and Medicine Annual: Grolier; 1995.

   

13.   Jacobson IM: Gallstones. In Grendell JH, McQuaid KR, Friedman SL, eds: Current Diagnosis and Treatment in Gastroenterology, Stamford: Appleton and Lange, 1996; 668-78.

   14.    Jacobson IM: The role ERCP before laparoscopic cholecystectomy. In: Jacobson IM, ed: ERCP and its Applications. Philadelphia: Lippincott, 1998; 95-104.

   

   15.    Jacobson I, Channapragada Srinivas: Diseases of the Bile Ducts. In: Friedman LS, Keeffe EB: Handbook of Liver Disease, Edinburgh: Churchill Livingstone, 1998; 465-80.

   

   16.   Jacobson IM: Sleisenger & Fordtran's Gastrointestinal and Liver Disease. Pathophysiology/Diagnosis/Management. Gastroenterology 1998; 115(1): 239-240 (Book Review).

   

17.   Spivak J, Jacobson IM: Endoscopic Management of Malignant Biliary Obstruction. In: Brandt LJ eds: Clinical Practice of Gastroenterology: Churchill Livingston, 1999.

   

   18.   Russo M, Jacobson I: Advice for testing and treatment of hepatitis C, Medical Society

   of the State of New York, 1999;54:3-4.

   

19.   Jacobson IM: Managing chronic hepatitis C virus infection. Hosp Physician 2001;37(1):34-41.

20.   Talal AH, Jacobson IM: Update on hepatitis C virus in HIV/HCV co-infection. National AIDS treatment advocacy program. Available at wwnatap.org/2001/jun/current061101. Accessed, 2001.

21.   Talal AH, Canchis PW, Jacobson IM: The HCV and HIV Coinfected Patient: what have we learned about pathophysiology? Current Gastroenterology Reports 2002; 4:15-22.

22.   Gotto AM, Jr, ed: The Cornell Illustrated Encyclopedia of Health, Washington, DC: Lifeline Press, 2002 (Editorial Advisory Board).

23.    Russo MW, Jacobson IM: Hepatocellular Cancer: Screening, Surveillance, and Prevention, in Kelsen DP, et al, eds: Gastrointestinal Oncology: Principles and Practice, Philadelphia: Williams and Wilkins, 2002, 559-568.

24.   Herrine SK, Jacobson I, Koff RS: Progress against hepatitis C infection: Patient Care 2002; 11-20.

25.   Russo MW, Jacobson IM: Nonalcoholic fatty liver disease: Hospital Physician, 2002; 26-41.

26.   Frissora CL, Jacobson IM: Gastrointestinal Manifestations of Diabetes, in Poretsky L, ed: Principles of Diabetes Mellitus, Boston: Kluwer, 2002;439-58.

27.   Jacobson IM, Gallstones, in Friedman SL, McQuaid KR, Grendell JH eds: Current Diagnosis and Treatment in Gastroenterology, New York: Lange, 2003;772-783.

28.   Purow D, Jacobson IM: Slowing the progression of chronic hepatitis B. Early antiviral therapy can help minimize complications. Postgrad Med. 2003;114(1):65-8, 73-6.

29.   Purow D, Jacobson IM: Chronic Viral Hepatitis: Diagnosis and Therapeutics, RS Koff and G Wu, eds., Humana Press, Totowa, NJ, 2001; Gastroenterology 2003;125:1278-1281 (book review).

30.   Jacobson IM: Imaging Overview in Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff’s Diseases of the Liver, ninth edition, Philadelphia: Lippincott, Willaims and Wilkins, 2003;281-286.

31.   Ahmed F, Jacobson IM: Hepatitis C, in Maddrey W, Atlas of the Liver, Philadelphia, Current Medicine, Inc., 2004, 18-145.

32.   Gonzalez, SA, Jacobson IM: The role of hematopoietic growth factors in special populations with chronic hepatitis C: patients with HIV coinfection, end-stage renal disease, or liver transplantation, Cleveland Clinic Journal of Medicine 2004;71 (3) S22-26.

33.   Jacobson I, Purow D: Disease of the bile ducts, in Friedman LS, Keeffe EB, Handbook of Liver Disease, Second Edition, Churchill Livingstone, 2004 Chapter 33:431-445.

34.   Ahmed F, Jacobson IM: Treatment of relapsers after combination therapy for chronic hepatitis C. Gastroenterol Clin North Am 2004; 33(3):513-526.

35.   Jacobson IM: Evaluation of suitability for therapy. McHutchison, JG: Management Issues in Hepatitis C Infection. Science Press Limited, 2004.

36   Ahmed F, Jacobson IM: Management of hematologic side effects: impact on compliance and efficacy. Hepatitis Reports 2005; 4:56-60.

37.   Butt AS, Jacobson IM: Hepatitis C: Making the diagnosis, Consultant 2005; 45(9): 955-959.

38.   Butt AS, Jacobson IM: Hepatitis C: latest treatment guidelines. Consultant 2005; 45 (9):960-962.

39.   Weitzman G, Jacobson IM: Peginterferon -2bin the treatment of hepatitis C. Future Virol. 2006; 1(3): 279-292.

40.   Ahmed F, Jacobson IM: Treatment of relapsers after combination therapy for chronic hepatitis C. Infect Dis Clin North Am. 2006; 20(1):137-153.

41.   Gambarin-Gelwan M, Jacobson IM: Treatment of Chronic Hepatitis B Infection. Gastroenterology and Hepatology Annual Review June 2006; (1):77-83.

42.   Gambarin-Gelwan M, Jacobson IM: Treatment of Nonresponders to Standard Hepatitis C Therapy. Current Hepatitis Reports 2006, 5:108-113.

43.   Ahmed F, Jacobson IM: Hepatitis C. In: Maddrey WC, Feldman M, eds. Atlas of    the Liver,4th Edition. Philadelphia: Current Medicine, 2006:127-168.

44.   Ahmed F, Coll D, Jacobson IM: Imaging. In Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff’s Diseases of the Liver. Tenth Edition. Philadelphia: Lippincott, Williams, and Wilkins, 2007:83-126.

45. Maddrey WC, Afdhal NH, Jacobson IM, Sulkowski MS: HCV Management Today and

Tomorrow: Tailoring Therapy by Genotype, Viral Response, and Novel Targets.

Gastroenterology and Hepatology 2007, 3(supplement 6) 4-14.

46.   Weisberg IS, Sigal SH, Jacobson IM: New Treatments for Hepatitis C: Life Cycle    Lessons. Current Hepatitis Reports 2007, 6:75-82.

47.   Jacobson IM: Commentary of a review of selected presentations on Utilizing Protease    and Polymerase Inhibitor Therapy in the Treatment of Active Hepatitis C.    Gastroenterology & Hepatology Vol 3, Issue 6, Suppl 21 June 2007, 12-14.

ABSTRACTS

   

   1.   Jacobson IM, Dienstag JL, Zachoval R, et al: The effect of hepatitis B vaccine on T-cells phenotypes: In vitro and in vivo studies. Hepatology 1983; 3:878.

   

   2.   Jacobson IM, Kelsey, PB: Endoscopy in patients with myocardial infarction. Gastrointestinal Endoscopy 1984;30:156-157.

   

   3.   Jacobson IM, Dienstag JL, Brettler D, Levin P, Mushahwar IK: Epidemiology of delta infection. Gastroenterology 1984;86:1123.

   

   4.   Colucci G, Jacobson IM, Lalatta F, Vernace S, Waksal SD, Weksler ME: Detection of hepatitis B Virus DNA, RNA and surface antigen in mononuclear cells from patients with type B hepatitis. Clinical Research 1986;34-2:648-A.

   

   5.   Weg AL, Soave R, Jacobson IM: The significance of intestinal blastocystis hominis infection. Gastroenterology 1987;92:1688.

   

   6.   Perrillo R, Davis G, Bodenheimer H, Lindsay K, Dienstag JL and the Hepatitis Interventional Study Group: A randomized, multicenter controlled trial of recombinant interferon alfa-2b, alone and following prednisone withdrawal, in chronic type B hepatitis. Hepatology 1987;7:1148.

   

    7.   Meschievitz C, Albrecht J, Langhvi B, Schiff E, Davis G, Perrillo R, Lindsay K, Bodenheimer H, Dienstag J, Balart L, Payne J, Tamburro C, Jacobson I, Carey W, O'Brien C, Sampliner R, Van Thiel D, Ortego T: Quality of life in patients with viral hepatitis. Hepatology 1988;8:1327.

   

    8.   Scudera PL, Aronne L, Jacobson IM: Liver test abnormalities in obese patients undergoing a weight reduction program. Hepatology 1988;8:1340.

   

    9.   Davis GL, Balart L, Schiff E, Lindsay K, Bodenheimer H, Perrillo R, Carey W, Jacobson I, Payne J, Dienstag J, Van Thiel DM, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Sanghvi B: Multicenter randomized controlled trial of alpha interferon treatment for chronic non-A, non-B hepatitis. Gastroenterology 1989;96:A591.

   

   10.   Perillo RP, Schiff E, Davis GL, Bodenheimer H, Lindsay K, Payne J, Dienstag JL, O'Brien C, Tamburro C, Jacobson I, Sampliner R, Feit D, Lefkowitch J, Kuhns M, Meschievitz C, Sanghvi B, Albrecht J: Multicenter randomized controlled trial of recombinant alpha interferon (rIFNa 2-b), alone or following prednisone withdrawal, in chronic hepatitis B (CHB). Hepatology 1989;10:579.

   

   11.   Bodenheimer HC, Lefkowitch J, Lindsay K, Davis G, Pezzullo J, Albrecht J, Balart L, Schiff E, Perrillo R, Carey W, Jacobson I, Payne J, Dienstag J, Van Thiel DH, Tamburro C, and the Hepatitis Interventional Study Group: Histological and clinical correlations in chronic hepatitis C. Hepatology 1990;12:844.

   

   12.   Lindsay KL, Davis GL, Bodenheimer HC, Albrecht J, Balart LA, Perrillo RP, Dienstag JL, Tamburro C, Schiff ER, Carey W, Payne J, Jacobson IM, Van Thiel DH, Lefkowitch J, and the Hepatitis Interventional Study Group: Predictors of relapse and response to retreatment in patients with an initial response to recombinant alpha interferon (rIFN) therapy for chronic hepatitis C. Hepatology 1990;12:847.

   

   13.   Davis GL, Lindsay K, Albrecht J, Bodenheimer HC, Balart LA, Perrillo RP, Dienstag JL, Tamburro C, Schiff ER, Carey W, Payne J, Jacobson IM, Van Thiel DH, Lefkowitch J, and the Hepatitis Interventional Therapy (HIT) Group: Predictors of response to recombinant alpha interferon (rIFN) treatment in patients with chronic hepatitis C. Hepatology 1990;12:905.

   

   14.   Lefkowitch JH, Schiff ER, Davis GL, Perrillo RP, Lindsay K, Bodenheimer HC, Balart LA, Ortego TJ, Payne J, Dienstag JL, Gibas A, Jacobson IM, Tamburro C, Carey W, Sampliner R, Van Thiel DH, Feit D, Albrecht J, Meschievitz C, Sanghvi B, and the Hepatitis Interventional Therapy (HIT) Group: Histologic features of hepatitis C (HC): Comparison with hepatitis B (HB) in two multicenter trials of recombinant alpha interferon (rIFN) therapy. Hepatology 1991;14:129A.

   

   15.   Dalton BH, Acosta A, Jacobson IM: Interferon therapy in HIV-positive patients with chronic hepatitis C. Hepatology 1992;16:199A.

   

   16.   Rakela J, Tong M, Shiffman M, Wright T, Hollinger FB, Fawaz K, Jacobson I, Peters M, Levine R, Black M, Balasubramaniam K, Donovan J, Foust R, Combes B, DePamphilis J, Sullivan-Bolvai J: An open-label, randomized, parallel evaluation of one, three, and six million units of interferon (IFN) alfa-2a in the six month treatment of patients with chronic non-A, non-B hepatitis (NANB). Gastroenterology 1993: 104:A976.

   

   17.   Hauptman WS, Jacobson IM: Predictors of response in patients with chronic hepatitis C treated with interferon alpha: experience at one center. Gastroenterology 1993:104:A913

   

   18.   Akerkar G, Roston A, Hitscherich R, Jacobson I: Relation of time course of liver tests to yield 漀昀 挀栀漀氀愀渀最椀漀最爀愀瀀栀礀 椀渀 瀀愀琀椀攀渀琀猀 眀椀琀栀 猀礀洀瀀琀漀洀愀琀椀挀 挀栀漀氀攀搀漀挀栀漀氀椀琀栀椀愀猀椀猀⸀  䄀洀 䨀 䜀愀猀琀爀漀攀渀琀攀爀漀氀漀最礀 ㄀㤀㤀㌀㬀 㠀㠀㨀㄀㔀㌀㈀ ⠀瀀爀攀猀攀渀琀攀搀 愀猀 瀀漀猀琀攀爀 愀琀 ㄀㤀㤀㌀ 洀攀攀琀椀渀最 漀昀 䄀洀攀爀椀挀愀渀 䌀漀氀氀攀最攀 漀昀 䜀愀猀琀爀漀攀渀琀攀爀漀氀漀最礀⤀⸀㰀戀爀⼀㸀☀渀戀猀瀀㬀☀渀戀猀瀀㬀☀渀戀猀瀀㬀㰀戀爀⼀㸀㄀㤀⸀☀渀戀猀瀀㬀☀渀戀猀瀀㬀☀渀戀猀瀀㬀刀漀猀琀漀渀 䄀Ⰰ 䨀愀挀漀戀猀漀渀 䤀䴀㨀  倀愀琀琀攀爀渀 漀昀 氀椀瘀攀爀 琀攀猀琀猀 愀猀 瀀爀攀搀椀挀琀漀爀 漀昀 礀椀攀氀搀 漀昀 挀栀漀氀愀渀最椀漀最爀愀瀀栀礀 椀渀 瀀愀琀椀攀渀琀猀 眀椀琀栀 猀礀洀瀀琀漀洀愀琀椀挀 挀栀漀氀攀搀漀挀栀漀氀椀琀栀椀愀猀椀猀⸀  䜀愀猀琀爀漀攀渀琀攀爀漀氀漀最礀 ㄀㤀㤀㐀 ⠀瀀爀攀猀攀渀琀攀搀 愀琀 䄀䜀䄀 吀漀瀀椀挀 䘀漀爀甀洀Ⰰ 䄀渀渀甀愀氀 䴀攀攀琀椀渀最 漀昀 䄀䜀䄀Ⰰ 䴀愀礀Ⰰ ㄀㤀㤀㐀⤀㰀戀爀⼀㸀㰀戀爀⼀㸀☀渀戀猀瀀㬀☀渀戀猀瀀㬀☀渀戀猀瀀㬀㈀ ⸀ ☀渀戀猀瀀㬀☀渀戀猀瀀㬀☀渀戀猀瀀㬀䬀愀甀爀 匀Ⰰ 䌀愀爀攀礀 圀䐀Ⰰ 䈀愀挀漀渀 䈀刀Ⰰ 䜀漀氀氀愀渀 䨀䰀Ⰰ 刀甀猀琀最椀 嘀䬀Ⰰ 昀漀爀 琀栀攀 一愀琀椀漀渀愀氀 䠀攀瀀愀琀椀琀椀猀 匀甀爀瘀攀椀氀氀愀渀挀攀 䜀爀漀甀瀀㨀 刀椀猀欀 昀愀挀琀漀爀猀 昀漀爀 瘀椀爀愀氀 栀攀瀀愀琀椀琀椀猀 䈀 愀渀搀 䌀 攀砀瀀漀猀甀爀攀 椀渀 猀甀戀樀攀挀琀猀 瀀爀攀猀攀渀琀椀渀最 琀漀 愀 瘀漀氀甀渀琀愀爀礀 氀愀爀最攀 猀挀愀氀攀 猀挀爀攀攀渀椀渀最 瀀爀漀最爀愀洀 ⠀䰀匀匀倀⤀ ⴀ 爀攀猀甀氀琀猀 漀昀 琀栀攀 一愀琀椀漀渀愀氀 䠀攀瀀愀琀椀琀椀猀 匀甀爀瘀攀椀氀氀愀渀挀攀 倀爀漀最爀愀洀⸀ 䜀愀猀琀爀漀攀渀琀攀爀漀氀漀最礀 ㄀㤀㤀㐀㨀㄀ 㘀㨀䄀㤀㄀㘀⸀㰀戀爀⼀㸀☀渀戀猀瀀㬀☀渀戀猀瀀㬀☀渀戀猀瀀㬀㰀戀爀⼀㸀☀渀戀猀瀀㬀☀渀戀猀瀀㬀☀渀戀猀瀀㬀㈀㄀⸀☀渀戀猀瀀㬀☀渀戀猀瀀㬀☀渀戀猀瀀㬀䬀爀愀眀椀琀琀 䔀䰀Ⰰ 刀愀欀攀氀愀 䨀 眀椀琀栀 琀栀攀 䠀攀瀀愀琀椀琀椀猀 匀琀甀搀礀 䜀爀漀甀瀀 愀渀搀 刀漀挀栀攀 䌀氀椀渀椀挀愀氀 刀攀猀攀愀爀挀栀㨀  刀攀琀爀攀愀琀洀攀渀琀 漀昀 爀攀氀愀瀀猀攀搀 挀栀爀漀渀椀挀 栀攀瀀愀琀椀琀椀猀 䌀 瀀愀琀椀攀渀琀猀 眀椀琀栀 攀猀挀愀氀愀琀攀搀 搀漀猀攀猀 漀昀 椀渀琀攀爀昀攀爀漀渀 愀氀昀愀ⴀ㈀愀㨀  愀渀 愀氀ernate strategy. Presented at the First International Conference on Therapies for viral hepatitis, Lihue, Hawaii, December 12-15, 1995.

   

   22.    Dienstag J, Schiff E, Wright T, Perrillo R, Hann H-W, Crowther L, Woessner M, Rubin M, Brown N, and the U.S. Lamivudine Investigator Group: Lamivudine treatment for one year in previously untreated U.S. hepatitis B patients: histologic improvement and hepatitis B e-antigen (HBeAg) seroconversion. Gastroenterology 1998;114:A1235.

   

   23.    Min A, Jones J, Esposito S, Lebovics E, Klion F, Jacobson I, Goldman I, Geders J, Tobias H, Branch A, Bodenheimer H, Jr: Early hepatitis C viral RNA decline during therapy with interferon alfa-2b and ribavirin in patients with chronic hepatitis C without sustained response to prior interferon.Gastroenterology 1998;114:A1302.

   

   24.    Geenen J et al: "Tannenbaum" Teflon stents vs traditional polyethylene stents for treatment of malignant biliary strictures: a multicenter, prospective randomized trial. Gastrointest Endosc 1998.

   

   25.    Min AD, Jones J, Esposito S, Lebovics E. Klion F, Jacobson I, Goldman I, Geders J, Tobias H, Branch A, Bodenheimer H, Jr: Interferon alfa-2b and ribavirin in patients with chronic hepatitis C without sustained response to prior interferon. Hepatology 1998;28:286A.

   

   26.    McHutchison J, Gordon S, Schiff E et al: Interferon alfa-2b alone or in combination with ribavirin in naive chronic HCV patients: A US multicenter trial. Hepatology 1998;28:387A.

   

   27.    Suharto TA, Jacobson I: Prevalence of hepatitis A antibodies HCV-infected persons in New York City. Am J Gastroenterol, 1998; 93:1680 (poster presentation, ACG Meeting 1998).

                         

28.    Min AD, Jones JL, Lebovics E, Jacobson IM, Klion FM, Goldman IS, Espositio S,

   Geders JM, Tobias H, Bodenheimer HC: Interferon alfa-2b and ribavirin in patients with

   Resistant chronic hepatitis C. Hepatology 1999;30:192A.

   

29.    Jacobson I, Lebovics E, Tobias H, Geders J, Klion F: Interferon alfa-2b and ribavirin

In treatment-naïve patients with chronic hepatitis C and normal ALT levels. Hepatology

1999; 30:459A.               

30.   Jacobson I, Russo MW, Brown RS, Lebovics E, Min A, Esposito S, Tobias H, lion F, Pizov O, Brass C, the NY Peg Intro Study Group: Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: A trial in prior nonresponders to interferon monotherapy or combination therapy, and in combination therapy relapsers. Gastroenterology 2001; 120 (5):145.

31.   Sood A, Russo MW, Jacobson IM, Talal A, Brown RS: A meta-analysis of transjugular intrahepatic portosystemic shunt (TIPS) for refractory ascites. Gastroenterology 2001; 120 (5): 150.

32.   Russo MW, Esposito S, Brown RS, Foulger KC, Jacobson, IM: Complementary-alternative medicine (CAM) use among patient with chronic hepatitis C infection (HCV). Gastroenterology 2001; 120 (5) :151.

33.   Lebovics E, Castillo E, Rampersaud P, Hirsch J, Casellas A, McFarlane C, Esposito S, Tobias H, Geders J, Jacobson I, Klion F, Wolf D: Comparison of hepatic iron content in African Americans and Caucasians with Hepatitis C. Gastroenterology 2001; 120 (5): 192.   

34.   Sood A, Reddy N, Russo M, Brown R, Jacobson I: Use of granulocyte colony stimulating factor (GCSF) for interferon induced neutropenia in patient with chronic hepatitis C infection. Hepatology 2001; 34 (4): 429A.

35.   Fiel I, Reddy N, Barritta D, Russo M, Jacobson, I: The intrazonal distribution of steatosis in chronic hepatitis C and the impact of hepatic steatosis on fibrosis and necroinflammatory activity. Hepatology 2001;34 (4): 221A.

36.   Jacobson I, Russo M,: Pegylated interferon alfa-2B plus ribavirin in patients with chronic hepatitis C: A trial in prior nonresponders to interferon monotherapy or combination therapy, and in combination therapy relapsers. Hepatology 2001; 34 (4):338A.

37.   Canchis W, Fiel I, Chiriboga L, Jacobson I, Yee H, Dieterich D: Hepatocyte and infiltrating hepatic lymphocite proliferation and apoptosis in HIV/HCV coinfected and HCV monoinfected individuals. Hepatology 2001; 34 (4): 438A.

38.   Bart G, Borg L, Piccolo P, Green M, Wells A, Ho A, Zhang L, Handy S, Schaefer R, Jacobson I, Kreek MJ: Current prevalence of hepatitis A, B, and C serologic markers, hepatitis C genotype, and viral load in former opiate addicts in methadone maintenance treatment. Hepatology 2001; 34 (4): 573A.

39.   Kumar KS, Russo, MW, Esposito S, Borcz A, Jacobson I, Brown M, Brown RS,: Severe pulmonary toxicity of interferon (IFN) and ribavirin (RIBA) therapy in chronic hepatitis C. Am J Gastroenterology 2001; 96(9): S127.

40.   Barritta D, Jacobson IM, Esposito S, Russo, MW: The effect of milk thistle (Silymarin) on serum alaine amnotransferase and viral levels in patients with chronic hepatitis C. Am J Gastroenterology 2001; 96(9):S117.

41.   Sood A, Jacobson IM, Russo MW: A meta-analysis of mortality and encepalopahty after transjugular introhepatic portosystemic shunt(TIPS) for refractory ascites. Am J Gastroenterology 2001; 96(9): S281.

42.   Canchis PW, Jacobson I, Talal A, Russo M, Bamji N, Davila J, Chiriboga L, Yee H, Fiel MI: Stellate cell activation in NASH, HCV/NASH, and normal liver biopsies. Gastroenterology 2002:122(4):A652.

43.   Canchis PW, Fiel MI, Bamji N, Davila J, Russo M, Chiriboga L, Yee H, Talal A, Jacobson I: Proliferation and apoptosis in liver biopsies from patients with hepatitis C and elevated -Fetoprotein. Gastroenterology 2002:122(4): A678.

44.   Jacobson IM, Russo MW, Brown RS Jr, Lebovics E, Min A, Esposito S, Tobias H, Klion F, Rovner D, Brass C, NY Peg Intron Study Group: Pegylated interferon Alfa-2b plus ribavirin in patients with chronic hepatitis C: A trial in prior nonresponders to interferon monotherapy or combination therapy and in combination therapy relapsers. Gastroenterology 2002:122(4): A626.

45.   Jacobson IM Russo MW, Lebovics E, Esposito S, Tobias H, Klion F, Brown RS, Dieterich D, Brass C, The NY Normal ALT Study Group: Interferon Alfa-2b ribavirin for patients with chronic hepatitis C and normal ALT: Final results. Gastroenterology 2002:122(4):A626.

46.   Bamji N, Russo MW, Talal A, Canchis PW, Davila J, Jacobson IM: Therapy with interferon decreases serum -Fetoprotein (AFP) levels in individuals with chronic hepatitis C (HCV). Gastroenterology 2002:122(4): A304.

47.   Anglade P, Russo MW, Talal A, Jacobson IM: Characteristics of patients with chronic hepatitis C and no fibrosis (Stage 0). Gastroenterology 2002: 122(4): A306.

48.   Purow DB, Bamji ND, Talal AH, Russo MW, Jacobson IM: Estimated rates of fibrosis progression in patients with chronic hepatitis C Do not accurately predict actual fibrosis progression: the importance of liver biopsy in making treatment decisions. Gastroenterology 2002:122(4): P160.

49.   Jacobson IM, Brown R Jr, Afdhal N, Rubin R, Spivey J, Freilich B, Bernstein D, Bass C, WIN-R Study Group: Effect of weight based ribavirin dosing on hematologic parameters: preliminary safely data from WIN-R. Gastroenterology 2002:122(4):P216.

50.   Marcellin P, Chang TT, Lim SG, Hadziyannis S, Tassopoulos N, Tong M, Sievert W, Shiffman M, Jeffers L, Goodman Z, Wulfsohn M, Xiong S, James C, Fry J, Brosgart C , the GS-98-437 and GS-98-438 Study Investigators: Adefovir dipivoxil (ADV) 10 mg for the treatment of chronic hepatitis B: Gastroenterolology 2002: 122(4).

51.   Gordon SC, Jacobson IM, Shiffman ML, Afdhal NH, McHutchison JG: A phaseII, 12-week study of Isis 14803, An antisense inhibitor of HCV for the treatment of chronic hepatitis C. Hepatology 2002: 36(4) 795.

52.   Brown R, Jacobson I, Afdhal N, Bubin R, Spivey J, Regenstein F, Bernstein D, Brass C, Freilic B, WIN-R Study Group: Racial/ethnic differences in hematologic toxicity of Peglated interferon and ribavirin therapy: analysis of the WIN-R trial. Hepatology 2002: 36(4) 518.

53.   Bart G, Piccolo P, Wells A, Ho A, Zhang L, Handy S, Schaefer R, Jacobson I, Kreek M: Hepatitis C virus and serologically silent hepatitis B virus coinfection in former opiate addicts in methadone maintenance treatment (MMT). Hepatology 2002: 36(4) 764.

54.   Jacobson IM, Russo MW, Brown Jr. RS, et al: Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: A trial in prior nonresponders to interferon monotherapy or combination therapy in combination therapy relapsers. Hepatology 2002;36:278A (abstract 782).

55.   Tong M, Schiff E, Jensen D, Jacobson I, Eversen G, McHutchison J, Aitchison R, Gordon GS, Babcock S, Enright J, Maloney L, Sandberg, Blatt L: Preliminary analysis of a phase II study of heptazyme, A nuclease resistant ribozyme targeting hepatitis C virus (HCV) RNA. Hepatology 2002: 36(4) 788.

56.   Jacobson I, Brown RS, Afdhal N, Rubin R, Spivey J, Freilich B, Regenstein F, Berstein D, Doig R, Brass C, WIN-R Study Group: Clinical correlates of HCV genotype and viral load: Findings from the WIN-R trial. Hepatology 2002: 36(4) 853.

57.   Jacobson I, Brown RS, Afdhal N, Rubin R, Freilich B, Regenstein F, Bernstein D, Doig R: Characteristics of HCV infection in African-Americans: Findings from the WIN-R trial. Hepatology October 2002: 36(4) 856.

58.   Russo MW, Teixeira A, Guarrera JV, et al: Kinetics of biochemical recovery in adult living donor liver transplantation (ALDT) is prolonged compared to cadaveric (CAD) transplantation. Hepatology 2002;36:196A (abstract 118).

59.   Canchis PW, Talal AH, Jacobson IM, Russo MW, et al: Hepatic stellate cell activation, hepatic stellate cell and hepatocyte proliferation and apoptosis in liver biopsies from individuals with HCV, steatohepatitis, and HCV/steatohepatitis. Hepatology 2002;36:278A (abstract 459).

60.   Balan V, Jacobson IM, Brown R, Afdhal N, Rubin R, Spivey J, Freilich B, Bernstein D, Sharma V, Brass C: Regional and racial variation of hepatitis C genotypes in the United States. Hepatology 2002: 36(4) 2194.

61.   Ahmed F, Jacobson I, et al: Clinical significance of pegylated interferon induced neutropenia: results from the WIN-R trial. Gastroenterology 2003; 124(4):A700 (abstract#213).

62.   Moss J, Chandra A, Gaglio P, Hafliger S, Dove L, Lobritto S, Jacobson I, Brown B: Suspicion, not standardized depression scores, increases adherence to pegylated interferon and ribavirin therapy for hepatitis C. Gastroenterology 2003; 124(4):P700 (abstract#216).

63.   Jacobson IM, Ahmed F, Russo MW, Brown RS, et al: Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: A trial in prior nonresponders to interferon monotherapy or combination therapy and in combination therapy relapsers: Final results. Gastroenterology 2003; 124(4):P714 (abstract#504).

64.   Gonzalez, SA, Shata TM, Dorante G, Jacobson IM, Talal AH: Hepatitis C virus-specific effector cell-mediated responses in transient virologic responders. Gastroenterology 2003; 124(4):P128 (Poster#M877).

65.   Ahmed F, Canchis PW, Talal AH, Petrovic LM, Jacobson IM: Impact of diabetes on chronic hepatitis C. Gastroenterology 2003;124(4):P150 (Poster #M1416).

66.   Golia P, Talal AH, Jacobson IM, Flynn S. Golia P: A preliminary study of growth factors versus dose reduction for peg interferon alfa-2b and ribavirin associated neutropenia and anemia in HIV/HCV co-infected patients. Gastroenterology 2003;124(4):P200 (Poster #T1207).

67.   Gordon SC, Bacon BR, Jacobson IM, Shiffman ML, Afdhal NH, Yu RZ, McHutchison JG, Kwoh TJ: Treatment of chronic hepatitis C with Isis 14803, an antisense inhibitor of HCV, given for 12 weeks. Hepatology 2003; 38(4):306A (Abstract #312).

68.   Raison CL, Broadwell SD, Borisov AS, Manatunga AK, Woolwine BJ, Jacobson IM, Neneroff CB, Miller AH: Depressive symptoms during IFN-alpha/ribavirin therapy are associated with reduced viral clearance in patients with hepatitis C. Hepatology 2003; 38(4):325A (Abstract #344).

69.   Raison CL, Borisov AS, Broadwell SD, Manatunga AK, Woolwine BJ, Jacobson IM, Neneroff CB, Miller AH: Depression during IFN-alfa plus ribavirin therapy: prevalence and prediction. Hepatology 2003; 38(4):326A (abstract #345).

70.   Canchis PW, Petrovic L, Ahmed F, Davila J, Fiel MI, Kim S, Teixeira A, Chiriboga L, Yee H, Edlin BR, Talal AH, Jacobson IM: Hepatocyte proliferation in hepatitis C: correlation with degree of liver injury and serum alpha-fetoprotein. Hepatology 2003; 38(4):464A (abstract #630).

71.   Ahmed F, Jacobson IM, Hargrave T, Lawitz E, Migicovsky B, Pines P, Reddy V, Terrault N, Brown RS, Brass C: Diabetes mellitus of new onset during pegylated interferon and ribavirin therapy for chronic hepatitis C: observations from the WIN-R trial. Hepatology 2003; 38(4):730A (abstract #1190).

72.   Ahmed F. Rovner D, Jacobson IM, Albert C, Brand M, Cox ME, Fixelle AM, Herrera J, Rustgi V, Wasserman RB, Brown RS, Brass C: Seizures during pegylated interferon and ribavirin therapy for chronic hepatitis C in the WIN-R trial. Hepatology 2003; 38(4):734A (abstract #1195).

73.   Ahmed F, Jacobson IM, Chen ST, Cofrancesco S, Cooley J, Demicco M, Freilich B, Hudes B, Jensen J, et al: Serious ophthalmologic events during pegylated interferon and ribavirin therapy for chronic hepatitis C: observations from the WIN-R trial. Hepatology 2003; 38(4):734A (abstract #1196).

74.   Moss JL, Senkbeil L, Gaglio P, Hafliger S, Dove L, Lobritto S, Jacobson I, Brown RS: Sustained viral response during HCV treatment is associated with higher depression scale scores. Hepatology 2003; 38(4):740A (abstract #1206).

75.   Senkbeil LE, Moss JG, Gaglio PJ, Dove LM, Lobritto SJ, Jacobson IM, Brown RS: Erythropoietin maintains ribavirin dose and sustained virologic response during HCV treatment. Hepatology 2003; 38(4):744A (abstract #1213).

76.   Azzam H, Ahmed F, Peterson B, Rovner D, Taylor N, Jacobson IM: Delayed recovery of pegylated interferon and ribavirin induced anemia. Hepatology 2003; 38(4):751A (abstract #1227).

77.   Ho E, Smith K, Patel K, Goron S, Pawlostsky JM, Jacobson I, McHutchison JG: An improved biomarker panel (FIBROSpect II for differentiating mild from more severe liver fibrosis in chronic HCV patients. Gastroenterology 2004; 126(4):P143 (Poster#S1639).

78.   Zhang C, Golia P, Jacobson I, Talal AH: Hepatic inflammatory cytokine mRNA expression in hepatitis C virus (HCV) and HCV/human immunodeficiency virus (HIV) co-infected patients. Gastroenterology 2004; 126(4):P235 (Poster#T1657).

79.   Lin A, Gonzalez SA, Marshall S, Tignor A, Ha T, Dorante G, Jacobson IM, Cunninghan-Rundles S, Talal AH: Effects of pegylated interferon-a on bright and dim natural killer cell activation in chronic hepatitis C infection. Gastroenterology 2004; 126(4):P235 (Poster#T1662).

80.   Ahmed F, Jacobson IM, Brown RS, Vierling J, Box T, Cochran JL, Gross JB, Matossian H, Rabinovitz M, Sahagun G, Sepe T. Brass C. Arrhythmias during pegylated interferon and ribavirin therapy for chronic hepatitis C: observations from the WIN-R trial. Gastroenterology 2004; 126(4):P720 (abstract #M1226).

81.   Gonzalez S, Jacobson IM: Clinical course of chronic hepatitis C in patients with very high serum alphafetoprotein levels and normal hepatic imaging. Gastroenterology 2004; 126(4):P745 (abstract#M2035).

82.   Jacobson I, et al: Weight based ribavirin dosing improves virologic response in HCV-infected genotype 1 African-Americans (AA) compared to flat dose ribavirin with peginterferon Alfa-2B combination therapy. Hepatology 2004; 33 (4) (abstract#125).

83.   McHutchison JG, Gordon SC, Afdhal NH, Jacobson IM, Krieg AM, Efler S. Al-Adhami M, David HL, Schmalbach TK: Human pharmacologic activity of a new TLR9 agonist antiviral, CPG 10101 (Actilon). Hepatology 2004; 40 (4), Suppl 1 (abstract #1224).

84.   Kadam JS, Gonzalez SA, Taylor NL, Rovner DN, Jacobson IM: Prognostic significance of positive TMA for HCV RNA with negative PCR after 24 weeks of peginterferon and ribavirin for chronic hepatitis C. Hepatology 2004; 40(4) (abstract # 356).

85.   McHutchison J, Bacon B, Gordon SC, Lawitz E, Shiffman M, Afdhal NH, Jacobson I, Muir A, Efler S, Al-Adhami, David H, Schmalbach T: Relationships of HCV RNA responses to CPG 10101, A TLR 9 Agnoist: pharmacodynamics and patient characteristics. Hepotology 2005; 42 (4) Suppl 1, (abstract #131).

86.   Raison CL, Pariante GM, Capuron L, Chen B, Woolwine BJ, Bruno C, Jacobson I, Miller A: The association of fatigue with poor virologic response in patients receiving interferon-alpha plus ribavirin for the treatment of hepatitis C. Hepatology 2005; 42 (4) Suppl 1, (abstract #1216).

87.   Schackman BR, Teixeira PA, Weitzman G, Mushlin A, Jacobson I. Quality of life tradeoffs for hepatitis C treatment: do patients and health professional agree? Hepatology 2005; 42 (4) Suppl 1 (abstract #385).

88.   McHutchison JG, Bacon BR, Gordon SC, Lawitz E, Shiffman M, Afdhal NH, Jacobson IM, Muir A, Efler S, Myette VK, Ahluwalia N, Murzenok PP, Lipford G, Schmalback TK, Krieg AM, Davis HL. Immunophenotyping profile of CPG 10101, a new TLR0 agonist antiviral for hepatitis C. Hepatology 2005; 42 (4) Suppl 1(abstract #873).

89.   O’Brien C, Godofsky E, Rodriguez-Torres M, Afdhal N, Pockros P, Lawitz E, Bzowej N, Rustgi V, Sulkowski M, Jacobson I, Chao G, Knox S, Pietropaolo K, Brown N. Randomized trial of valopicitabine (NM283), alone or with peg-interferon, vs. retreatment with peg-interferon plus ribavirin (PEGIFN/RBV) in hepatitis C patients with previous non-response to pegifn/RBV: first interim results. Hepatology 2005; 42 (4) Suppl. 1 (abstract #95).

90.   Jacobson IM, Brown RS, Freilich B, Afdhal N, Kwo Paul, Becker S et. Weight-based Ribavirin dosing (WBD) increases sustained viral response (SVR) in patients with chronic hepatitis C (CHC): final results of the Win-R study, a US community based trial. Hepatology 2005; 42 (4) Suppl. 1 (abstract #LB03).

91.   Pockros P, O'Brien C, Godofsky E, Rodriguez-Torres M, Afdhal N, Pappas S, Lawitz E, Bzowej N, Rustgi V, Sulkowski M, Sherman K, Jacobson I, Chao G, Knox S, Pietropaolo K, Brown N: Valopicitabine (NM283), Alone or with Peg-Interferon, Compared to Peg Interferon/Ribavirin (pegIFN/RBV) Retreatment in Hepatitis C Patients with Prior Non-Response to PegIFN/RBV: Week 24 Results. Gastroenterology 2006; 130 (4) Suppl 2 (abstract #4).

92.   Afdhal N, Jacobson I, Brown R, Freilich B, Santoro J, Griffel L, Brass C: The Win-R Study Group. The Effect of Liver Fibrosis and Cirrhosis on SVR in 4913 Patients with Hepatitis C; Results from the Win-R Trial. Gastroenterology 2006; 130 (4) Suppl 2 (abstract #655).

93.   Brown RS, Jacobson IM, Afdhal N, Freilich B, Regenstein F, Flamm S, Kwo P, Pauly M, Griffel LH, Brass CA: Differences In Treatment Outcome To Antiviral Therapy Based On Genotype And Viral Load In Hepatitis C Genotypes 2 And 3 In The WIN-R Trial. Gastroenterology 2006; 130 (4) Suppl 2 (abstract #523).

94.   Pauly MP, Sheinbaum AJ, Szpakowski J, Ready JB, Brown RS, Freilich B, Afdhal N, Kwo P, Santoro J, Becker S, Jacobson I, Griffel L, Brass C: The influence of cigarette smoking on response to treatment with pegylated interferon alfa-2b and ribavirin in patients with chronic hepatitis C. Gastroenterology 2006; 130 (4) Suppl 2 (abstract #S1923).

95.   Kwo P, Jacobson I, Brown R, Freilich B, Afdhal N, Santoro J, Becker S, Wakil A, Pound D, Godofsky E, Strauss R, Bernstein D; Flamm S, Bala N, Arraya V, Davis M, Monsour H, Vierling J, Regenstein F, Balan V, Dragutsky M, Epstein M, Herring R, Griffel LH, Brass C: Prior HCV Treatment Experience and its Relationship To Sustained Virologic Response (SVR): An Analysis of the WIN-R Study Database, A US Academic Community Based Trial. Gastroenterology 2006; 130 (4) Suppl 2 (abstract #T1802).

96.   Jacobson IM, Brown RS, Freilich B, Afdhal N, Kwo P, Santoro J, Becker S, Wakil A, Pound D, Ahmed F, Griffel LH, Brass CA: G. Stratification of High Viral Load: Impact on Sustained Virologic Response in the WIN-R Trial. Gastroenterology 2006; 130 (4) Suppl 2 (abstract #T1806). Gastroenterology 2006; 130 (4) Suppl 2 (abstract #T1806).

97.   Kadam JS, Jones K, Peterson R, Dove L, Pearce D, Hassanein T, Doonquah L, Glesby M, Heller L, Aboulafia D, Rodriguez J, Bonilla H, Galpin J, Aberg J, Johnston B, Liu R, Jacobson IM, Talal AH: Growth Factors Versus Dose Reduction for Pegylated Interferon Alfa-2b and Ribavirin Associated Neutropenia and Anemia in HIV/HCV Co-Infected Patients. Gastroenterology 2006; 130 (4) Suppl 2 (abstract #T1810).

98.   Feilich B, Hu K-Q, Jacobson I, et al: Prospective Analysis of sustained Virologic Response (SVR) to Peg-Interferon (Peg IFN) Alfa-2 and Ribavirin Treatment in Asian and Hispanic Patients with Chronic Hepatitis C: Results from the Win-R Trial. Hepatology 2006: 44 (4) Suppl 1 (abstract #349).

99.   Brown R, Jacobson I, Nezam A, Freilich B, Pauly MP, Regenstein F, Flamm S, Kwo P, Becker S, Griffel L, Brass C; Risk Factors for Relapse in Genotype 3 High Viral Load Patients with Hepatitis C in the Win-R Trial. Hepatology 2006: 44 (4) Suppl 1 (abstract #1132).

100.   Jacobson I, Pockros P, Benhamou Y, Esteban-Mur R, Lurie Y, Flisiak R, Afdhal N, Kim Y, Xu Y, Murphy B; Impact of Taribavirin and Ribavirin Exposure on Efficacy and Anemia Rates When Combined with Pegylated Interferon Alfa-2 in the Treatment of Chronic HCV. Hepatology 2006: 44 (4) Suppl 1 (abstract #1133).

101.    Jacobson IM, Ghalib R, Lawitz E, Freilich B, Gordon SC, Kwo P, Riley TR, Bright D, Morris ML, Al-Adhami M, Himes JL, Massari FE, McHutchison JG; Early Viral Response and on Treatment Response to CPG 10101 (Actilontm), in Combination with Pegylated Interfereon and/or Ribavirin, in Chronic HCV Genotype 1 Infected Patients with Prior Relapse Response. Hepatology 2006: 44 (4) Suppl 1 (abstract #96).

102.   Flamm SL, Jacobson IM, Brown R, Freilich B, Afdhal N, Kwo P, Santoro J, Becker S, Wakil A, Pound D, Harvey J, Griffel LH, Brass CA; Pegylated Interferon Alfa 2 Ribavirin are Equally Efficacious and Well Tolerated in Patients > 65 Years Old in Comparison to Other Age Groups: Subanalysis of a Randomized, Controlled Study (Win-R Trial). Hepatology 2006: 44 (4) Suppl 1 (abstract #338).

103.    Jacobson IM, Brown R, Freilich B, Afdhal Z, Kwo P, Santoro J, Becker S, Wakil A, Griffel L, Brass C; Response to Peginterferon Alfa-2 and Ribavirin for Chronic Hepatitis C in Patients with Body weight > 125 KG: Results from the Win-R Trial. Hepatology 2006: 44 (4) Suppl 1 (abstract #369).

104.   Everson GT, Tong MJ, Jacobson IM, Jensen DM, Haller AA, Lauer GM, Parker J, Ferraro J, Cruickshank SE, Duke RC, Apelian D, Rodell TC, Schiff ER; Interim Results from a randomized, double-blind, placebo-controlled phase 1B study in subjects with chronic HCV after treatment with G1-5005, A yearst-based HCV immunotherapy targeting NS3 and core proteins. Hepatology 2006: 44 (4) Suppl 1 (abstract #LB17).

105.   Shiffman ML, Ghalib R, Lawitz E, Freilich B, Gordon SC, Kwo PY, Riley RT, Schiff E, Flamm S, Jacobson IM, Zein NN, Reuben A, Swim M, Bright D, Al-Adhami M, Lekstrom-Himes J, Massari EF, McHutchison JG. CPG 10101 (Actilon) in combination with Pegylated interferon and/or ribavirin in chronic HCV genotype 1 infected patients with prior relapsed response: week 48 data. Journal of Hepatology 2007: 46, Suppl 1 (abstract #649).

106.   McHutchison JG, Everson GT, Gordon S, Jacobson I, Kauffman R, McNair L, Muir A. Results of an interim analysis of a phase 2 study of telaprevir (vx-950) with peginterferon a-2a and ribavirin in previously untreated subjects with hepatitis C. Journal of Hepatology 2007: 46 Suppl 1 (abstract # 786).

107.   Afdhal N, O’Brien C, Godofsky E, Rodriguez-Torres M, Pappas SC, Lawitz E, Pockros P, Sulkowski M, Jacobson I, Chao G, Knox S, Pietropaolo K, Broan NA, Valopiticitabine 04 Study Group. Valopicitabine (MN283) alone or with Peginterferon, compared to PEG interferon/ribavirin (PEGIFN/RBV) retreatment in patients with HCV-1 infection and prior non-response to PEGIFN/RBV: one-year results. Journal of Hepatology 2007: 46 Suppl 1 (abstract # 6).

LETTERS

1.   Jacobson IM, Isselbacher KJ: Amyloidosis and hyposplenism with leukocytosis and thrombocytosis. Ann Intern Med 1983;99:573.

2.   Fine SN, Eisdorfer RM, Miskovitz PF, Jacobson IM: Losec or Lasix? N Eng J Med 1990;322:1674.

3.   Rahmin M, Jacobson IM: ERCP in pregnancy, American Journal of Gastroenterology 1994; 89:1601-2.

4.   Rahmin MG, Tighe M, Jacobson IM: Safety of ERCP during an acute MI. American Journal of Gastroenterology 1995;90:518.

5.   Jacobson IM, McHutchison J: Response to article by Formann et al. J Viral Hepatitis 2003; 11:187.

6.   Weitzman G, Jacobson I: Cost effectiveness in Hepatitis. Annals of Internal Medicine 2005;143 (10): 757-8.

Honors and Awards

Dr. Jacobson is the recipient of numerous honors and awards, some of which include:

1974:Phi Beta Kappa, Yale University

1975: Yale University: summa cum laude

1978:Alpha Omega Alpha Columbia University College of Physicians and Surgeons

1978: Columbia University College of Physicians and Surgeons: Alpha Omega Alpha

1979: Columbia University College of Physicians and Surgeons: Robert F. Loeb Award for Excellence in Clinical Medicine, Herbert J. Bartelsone Award in Pharmacology, Dr. Harold B. Stevelman Award in Cardiology, Urology Prize

1998: Two research awards of the American Liver Foundation named for Ira Jacobson, MD. “Ira M. Jacobson, MD Award” and “Ira M. Jacobson, MD, 1997 Nucraft Dental Award”.

President, New York Society for Gastrointestinal Endoscopy

President, New York Gastroenterological AssocIation